Form 4: Helius Medical Technologies' Chief Medical Officer Granted Stock Options

Antonella R. Favit-Van Pelt, Chief Medical Officer of Helius Medical Technologies, received a grant of 277,000 stock options on July 2, 2024.

Summary

• On July 2, 2024, Antonella R. Favit-Van Pelt, the Chief Medical Officer of Helius Medical Technologies, Inc., was granted 277,000 stock options.
• The options have an exercise price of $0.965 per share.
• 62.5% of the options vested immediately, with the remaining options vesting in equal quarterly installments over the next ten quarters, starting September 30, 2024.
• The options expire on July 1, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to align executive incentives with shareholder value.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Helius Medical Technologies, Chief Medical Officer, executive compensation, HSDT, Antonella R. Favit-Van Pelt, equity incentive plan